|
|
Kontoghiorghes G J.
Prospects for introducing deferiprone as potent pharmaceutical antioxidant.
Frontiers Bioscience 2009; E1: 161-78.
|
|
|
Kontoghiorghes G J.
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
Expert Opinion Drug Safety 2008; 7(6):1-2.
|
|
|
Kontoghiorghes G J.
Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide.
Hemoglobin 2008; 32: 608 - 615.
|
|
|
Kontoghiorghes GJ, Efstathiou A, Ioannou-Loucaides S, Kolnagou A.
Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
Hemoglobin. 2008;32:217-227.
|
|
|
Fukuda S, Ikeda M, Nakamura M, Katoh A, Yan X, Xie Y, Kontoghiorghes GJ.
The effects of bicarbonate and its combination with chelating agents used for the removal of depleted uranium in rats.
Hemoglobin. 2008;32:191-198.
|
|
|
Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Hemoglobin. 2008;32:41-47.
|
|
|
Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone.
Hemoglobin. 2008;32:17-28.
|
|
|
Kontoghiorghes GJ.
Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/Deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox.
Hemoglobin. 2008;32:1-15.
|
|
|
Kontoghiorghes G J.
Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities.
Expert Opin. Drug Saf. (2007) 6(3):235-239.
|
|
|
Kontoghiorghes G J, Kolnagou A.
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Haematologica 2006; 91:(ELT) 04. |
|
|
Kontoghiorghes G J.
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Hemoglobin 2006; 30:329-347. |
|
|
Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes G J.
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. the importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Hemoglobin 2006; 30: 219-227. |
|
|
Kolnagou A, Kontoghiorghes G J.
Effective combination therapy of deferiprone and desferrioxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. the protocol of the international committee on oral chelators.
Hemoglobin 2006; 30: 239-249. |
|
|
Kontoghiorghes G J.
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Hemoglobin 2006;30:183-200. |
|
|
Fukuda S, Ikeda M, Anzai K, Suzuki M, Katoh A, Kontoghiorghes G J.
Radiation protection by deferiprone in animal models.
Hemoglobin 2006; 30: 201-208. |
|
|
Kontoghiorghes GJ.
New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Expert Opin Emer Drugs. 2006; 11: 1-5. |
|
|
Peng CT, Fucharoen S, Kontoghiorghes GJ, Tsai CH.
Report on the Proceedings of the 15(th) International Conference on Oral Chelation (ICOC) in the Treatmentof Thalassemia and Other Diseases at Taichung, Taiwan, April 22-26, 2005.
Hemoglobin. 2006; 30: 63-68. |
|
|
Kontoghiorghes GJ.
Effects of ICL670 (deferasirox) on cardiac iron concentrations.
Lancet. 2005; 366:804. |
|
|
Kontoghiorghes GJ, Kolnagou A, Eracleous E, Evans RW.
Iron mobilisation from transferrin by deferiprone (L1).
Br J Haematol. 2005; 129:157 |
|
|
Kontoghiorghes GJ.
New oral iron-chelating drugs for the treatment of transfusional iron overload and other diseases.
Drugs Future. 2005; 30: 1241-51. |
|
|
Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
Advances in iron overload therapies. Prospects for effective use of deferiprone(L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations.
Curr Med Chem. 2005; 12: 2663-81. |
|
|
Kontoghiorghes GJ, Kolnagou A.
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators.
Curr Med Chem. 2005; 12: 2695-710. |
|
|
Kontoghiorghes GJ.
Regulatory molecules and chelators used for the control of essential and toxic metals in health and disease: From molecular interactions to clinical effects and applications.
Curr Med Chem. 2005; 12: 2661-2. |
|
|
Kolnagou A, Fessas Ch, Papatryphonas A, Economides Ch, Kontoghiorghes GJ.
Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia.
Brit J Haematol. 2004; 127:360-1. |
 |
Kontoghiorghes GJ, Pattichis K, Neocleous K,
Kolnagou A.
The design and development of
deferiprone (L1) and other iron chelators for
clinical use: targeting methods and application
prospects. Curr Med Chem. 2004;11:2161-83 |
 |
Kontoghiorghes GJ.
Do we need more iron
chelating drugs. Lancet. 2003; 362: 495-6. |
 |
Kontoghiorghes GJ, Neocleous K, Kolnagou A.
Benefits and risks of deferiprone in iron
overload in thalassaemia and other conditions.
Comparison of epidemiological and therapeutic
aspects with deferoxamine. Drug Saf. 2003; 26:
553-84. |
|
|
Kontoghiorghes GJ, Kolnagou A.
Deferiprone versus desferrioxamine in
thalassaemia, and T2* validation and utility.
Lancet. 2003; 361:184. |
 |
Douvas GS, May MH, Kolnagou A, Kontoghiorghes G J.
Effects on Mycobacterium avium
replication in normal human macrophages by
deferiprone (L1) and other iron chelators.
Possible implications on toxicity.
Arzneimittelforschung. 2002;52:45-52. |
 |
Kontoghiorghes GJ.
Clinical use,
therapeutic aspects and future potential of
deferiprone in thalassemia and other conditions
of iron and other metal toxicity.
Drugs Today (Barc). 2001 ;37:23-35. |
|
|
Pashalidis I and Kontoghiorghes GJ.
Molecular factors
affecting the complex formation between deferiprone (L1)
and Cu(II).
Arzneimittel-Forschung / Drug Research
2001, Volume 51 (II), pages 998-1003
|
|
|
Kontoghiorghes GJ. Clinical use, therapeutic aspects and future
potential of deferiprone in thalassaemia and other
conditions of iron and other metal toxicity. Drugs
of Today 2001, Volume 37, pages 23-35. |
 |
Pashalidis
I and Kontoghiorghes GJ. Interaction of
L1-Deferiprone with Cu(II) and U(VI) ions. Chemical
characterisation of solid phases and possible clinical
application. Biomarkers and Environment 2001, Volume
4 (suppl 1), pages 80-81. |
| |
Kontoghiorghes GJ, Sitarou M, Pattichi K and Kolnagou A. Iron
overload toxicity and new therapeutic strategies with
the orally effective chelating drug deferiprone (L1). Biomarkers
and Environment 2001, Volume 4 (suppl 1), pages 16-21. |
|
Kontoghiorghes GJ, Agarwal MB, Grady RW, Tondury P and Marx
JJ. Deferiprone
or fatal iron toxic effects?. Lancet 2001, Volume 357,
pages 882-883. |
|
Kontoghiorghes
GJ, Sitarou M, Pattichis K, Hadjigavriel M and Kolnagou
A. Present status and future prospects of oral
chelation with L1-deferiprone and other orally active
chelators. SO.S.T.E. Notiziario 2001, Volume 2 (1),
pages 98-101 |
|
Kontoghiorghes GJ, Agarwal MB, Grady RW, Kolnagou A and Marx
JJ. Deferiprone
for thalassaemia. Lancet 2000, Volume 356, pages
428-429. |
|
Pashalidis
I and Kontoghiorghes GJ. Competition studies of
L1-deferiprone with copper and iron. Possible
implications on efficacy, toxicity and new therapeutic
applications. Transfusion Science 2000, Volume 23,
pages 259-261. |
|
|
Kontoghiorghes GJ, Pattichi K, Hadjigavriel M and Kolnagou A. Transfusional
iron overload and chelation therapy with deferoxamine
and deferiprone (L1). Transfusion Science 2000,
Volume 23, pages 211-223. |
|
Paschalidis
I and Kontoghiorghes GJ. Effective complex
formation in the interaction of
1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1)
with uranium(VI). Journal of Radioanalytical and
Nuclear Chemistry 1999, Volume 242, pages 181-184. |
| |
Eybl
V, Kotyzova D, Koutensky J, Migkova V, Sykora J and
Kontoghiorghes GJ. The influence of deferiprone
(L1) and deferoxamine on the level of essential elements
in mice. Biomarkers and Environment 1999, Volume
3, pages 25-28. |
